Novo Nordisk saw a competitor’s bet and raised the stakes in metabolic dysfunction-associated steatohepatitis (MASH) with its planned up-to-$5.2 billion acquisition of Akero Therapeutics.
Fusing Oncolytic Virotherapy With Cancer Immunotherapy to Treat Therapy-Resistant Melanoma In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492), polatuzumab vedotin plus rituximab, ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with new-onset type 1 diabetes receiving ...
Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...
India, Sept. 26 -- In a clear show of solidarity with Afghanistan, India has delivered three container loads of vital humanitarian aid to Kabul through Iran's Chabahar port today, despite mounting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback